1 of 46    
  
 
  
COMIRB  PROTOCOL  #: 14-0909 
PROTOCOL  VERSION: April 27, 2018 
 
  
 
PROTOCOL  TITLE:  An open label, randomized, Phase II trial of Metabolic complications in patients  
treated  with enzalutamide vs standard ADT for the treatment of hormone 
sensitive prostate cancer  
 
[STUDY_ID_REMOVED] 
 
 
COORDINATING  CENTER:  University of Colorado Cancer Center  
 
 
LEAD PRINCIPAL  INVESTIGATOR:  Elizabeth Kessler,  MD 
University of Colorado Denver, Division of Medical Oncology 
12801 East 17th Avenue, MS 8117 
Aurora, CO 80045 
Phone: 720-848-0402 
Fax: 303-724-3889 Elizabeth.kessler@ucdenver.edu  
 
 
 
Statistician:  
Dexiang Gao, PhD 
2 of 46   COMIRB/Protocol # 14-0909 
Protocol Version: 4.27.2018 PI:  Dr. Kessler  
 
 
 
Protocol Summary 
 
 
An open label, randomized, Phase II trial of Metabolic complications in patients treated with 
enzalutamide vs standard ADT for the treatment of hormone sensitive prostate cancer  
Primary Objective  To determine  the incidence  of metabolic  syndrome  within  12 months,  as defined  by 
the Adult Treatment Panel III, in patients treated with enzalutamide compared to 
standard androgen deprivation  therapy. 
Secondary 
Objectives In patients on enzalutamide versus traditional ADT:  
 To determine the incidence of metabolic syndrome within 6 months, as 
defined by the Adult Treatment Panel III, in patients treated with 
enzalutamide compared to standard androgen deprivation  therapy.  
 To assess bone health, as measured by a DXA  scanner  
 To assess body composition (sarcopenic obesity), as measured by cross 
sectional CT  analysis  
 To assess QOL, as measured by the FACT -P and  SHIM  
 To assess time to PSA progression and time to radiographic progre ssion. 
Progression will be defined as lack of clinical  benefit  in the setting  of either 
rising PSA, growth of visceral or soft tissue metastasis, or development of 
new bone metastasis as defined per  protocol  
 To assess the incidence of developing individual  risk factors, or 
components, which comprise metabolic syndrome  
 To assess the safety and tolerance of enzalutamide or  ADT  
 To assess the change in hs- CRP as a marker of  inflammation  
 To assess the change in physical function as measured  by the Short Physical  
Performance Battery  
Study Population  Patients with biochemically recurrent disease, metastatic disease, and patients offered ADT as primary therapy if they are not candidates for local therapy.  
Other Participating Site (enrolling 
subjects)  University of  Colorado Health - Poudre Valley Hospital (UCH-North) 
Site Principal Investigator:  Steven Schuster, MD  
STUDY DESIGN 
Multi -center, open label, randomized, phase II trial evaluating the incidence of metabolic syndrome 
within 12 months in patients treated with enzalutamide in comparison with androgen deprivation therapy 
for treatment of advanced prostate cancer. Enzalutamide 160mg orall y daily versus standard androgen 
deprivation therapy. Acceptable forms of ADT will be specified and this therapy must result in castrate levels of testosterone. Patients will be treated for a 12 -month period and assessed for the development of 
metabolic sy ndrome at 3 month intervals. Patients with continued clinical benefit beyond the 12-month 
endpoint may continue on their assigned treatment through standard of care prescribing methods.  
  
 
 
TABLE 1: Schedule of Events  Screening  
Day 0  Start of 
Treatment 
Month 1, Day12 Month 2, 
Day1  Month 4,  
Day 1  Month 7,  
Day 1  Month 10,  
Day 1  Month 13, Day  
1 
End of 
Treatment  End of 
study6 
Informed Consent  X        
VISIT ASSESSMENTS          
Adverse events assessment  X X X X X X X X 
Review medication list  X X X X X X X X 
Physical Exam and history  X X X X X X X X 
Vital signs, including weight, waist circumference  X X X X X X X X 
Height  X        
Performance Status  X X X X X X X X 
LABORATORY STUDIES          
CBC, Comprehensive metabolic panel (fasting for 
glucose)  X1 X X X X X X X8 
PSA X X7 X X X X X  
Lipid Profile (including triglycerides and HDL)  X   X X X X  
N-Telopeptide, Bone specific alkaline phosphatase, 
hs-CRP, estradiol   X  X X X X  
Testosterone  X  X X X X X  
25-OH Vitamin D  X    X  X  
IMAGING          
Fill out QOL questionnaires (FACT – P and SHIM)   X  X X X X  
Bone densometry (DXA)   X9  X   X9  
CT scan of chest, abdomen, pelvis3, 4 X    X  X  
Nuclear Bone scan3,4 X    X  X  
TREATMENT          
Enzalutamide dosed at 160mg po daily   X X X X X   
GNRH agonist/antagonist (Standard of care)   X X X X X   
Calcium/Vitamin D5  X X X X X   
OTHER          
Short physical performance battery   X  X X X X  
Optional biomarker blood testing (3 tubes, see lab 
manual)   X  X X X X  
1 May be performed from day -14 to 0.  Screening is day  0. 
2 Day 1 Month 1 must occur with 21 days of screening.  Visit days of the remaining months must occur +/ - 5 days to date on the calendar. 
3 May be performed Day - 28 - Day 0 
4 Also to be performed during treatment to evaluate a rising PSA. CT chest combined with MRI of the abdomen/pelvis is also accepted.  
5 At least 1000mg of calcium and 800 International Units (IU) of vitamin D  
3 of 46 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
4 of 46   
  
6. Safety visit to be performed within 30 days from last study drug dose, or prior to starting a new treatment, whichever is sooner 
7 If screening PSA is within 5 days of Day 1, repeat testing is not necessary  
8 Glucose does not have to be  fasting  
9 Please see protocol for windows as DXA and NM bone scan need 14 days of separation if bone scan is performed  first 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
5 of 46   
  
 
Table of Contents  
LIST OF ABBREVIATIONS AND GLOSSARY  OF TERMS  ......................................................................................... 8  
1. BACKGROUND AND  STUDY  RATIONALE  ........................................................................................................... 10 
1.1 Prostate cancer  ..................................................................................................................................................................... 10 
1.2 Androgen deprivation therapy and metabolic  syndrome  ..................................................................................... 10 
1.3 Metabolic  syndrome  ........................................................................................................................................................... 10 
1.4 Rationale for  study  design  ................................................................................................................................................ 11 
1.5 Enzalutamide  ......................................................................................................................................................................... 11 
1.6 Androgen deprivation therapy  ....................................................................................................................................... 12 
1.7 Nonclinical Experience  ...................................................................................................................................................... 13 
1.7.1 Drug Metabolism  and Pharmacokinetics  ............................................................................................................................... 13 
1.8 Toxicology  .............................................................................................................................................................................. 13 
1.8.1 Drug- Drug Interaction  Risk  Assessment  ................................................................................................................................ 13 
2. STUDY  OBJECTIVES  .................................................................................................................................................. 14 
2.1 Primary Objectives  .............................................................................................................................................................. 14 
2.2 Secondary  Objectives .......................................................................................................................................................... 14 
3. STUDY  ENDPOINTS  ................................................................................................................................................... 14 
3.1 Primary Endpoints  .............................................................................................................................................................. 14 
3.2 Secondary  Endpoints  ..........................................................................................................................................................  14 
4. STUDY DESIGN  ........................................................................................................................................................... 15 
4.1 Overview of  Study  Design  ................................................................................................................................................. 15 
4.2 Duration of  Study  ................................................................................................................................................................. 15 
4.3 Overview  of treatment  ....................................................................................................................................................... 16 
4.4 Criteria for Dose  Administration .................................................................................................................................... 16 
4.4.1 Study  Drug Administration  .......................................................................................................................................................... 16 
4.4.2 Clinical  Benefit  .................................................................................................................................................................................. 16 
4.5 Dose  Modification Guidelines  .......................................................................................................................................... 17 
4.6 Study specific  biomarker collection  .............................................................................................................................. 17 
5. STUDY POPULATION  ................................................................................................................................................ 17 
5.1 Inclusion Criteria  ................................................................................................................................................................. 17 
5.2 Exclusion Criteria  ................................................................................................................................................................. 17 
6. STUDY PROCEDURES  AND  ASSESSMENTS ........................................................................................................ 19 
6.1 Informed  Consent  ................................................................................................................................................................ 19 
6.2 Randomization  ......................................................................................................................................................................
 19 
6.3 Study  Visits  ............................................................................................................................................................................. 19 
6.3.1 Physical  Examination  .....................................................................................................................................................................  19 
6.3.2 Schedule  of Events ...........................................................................................................................................................................  19 
7. STUDY  ASSESSMENTS .............................................................................................................................................. 22 
7.1 Assessment of  metabolic  syndrome  .............................................................................................................................. 22 
7.2 Efficacy  Evaluations  ............................................................................................................................................................ 22 
7.2.1 PSA ......................................................................................................................................................................................................... 22 
7.2.2 Radiographic evaluation  ............................................................................................................................................................... 22 
7.3 Body  composition  evaluation  .......................................................................................................................................... 23 
7.4 Quality of  life assessment  ................................................................................................................................................. 23 
7.5 Physical  function evaluation  ............................................................................................................................................ 23 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
6 of 46   
 7.6 Safety  evaluations  ................................................................................................................................................................ 23 
7.6.1 Adverse Events  ................................................................................................................................................................................. 24 
7.6.2 Clinical  Laboratory Evaluations  ................................................................................................................................................. 24 
7.7 Concomitant Medication  and  Therapies ...................................................................................................................... 24 
7.8 Completion  of Study  ............................................................................................................................................................ 25 
7.9 Study  Compliance ................................................................................................................................................................. 25 
8. INVESTIGATIONAL  AGENTS ................................................................................................................................... 26 
8.1 Precautions  and  Restrictions  .......................................................................................................................................... 26 
8.2 Description of Investigational  Agents  .......................................................................................................................... 26 
8.2.1 Enzalutamide ..................................................................................................................................................................................... 26 
8.2.2 Androgen deprivation therapy ................................................................................................................................................... 26 
8.3 Preparation, Reconstitution,  and  Dispensation ........................................................................................................ 26 
8.4 Storage,  Handling, Accountability  .................................................................................................................................. 26 
8.4.1 Enzalutamide ..................................................................................................................................................................................... 26 
8.4.2 Handling  and Accountability  ....................................................................................................................................................... 27 
9. STUDY CONDUCT  ....................................................................................................................................................... 27 
9.1 Oversight of multiple  participating  sites  ..................................................................................................................... 27 
Study will be conducted at multiple sites with the University of Colorado Anschutz Campus as the  
coordinating site. Dr. Kessler, as the Lead PI, will work with the Site PI(s) to insure proper training and  
conduct  ................................................................................................................................ ...........................................................  27 
9.2 Arrangements for Recruitment  of Patients  ................................................................................................................ 27 
9.3 Treatment  Group  Assignments  ....................................................................................................................................... 28 
10. STATISTICAL AND  QUANTITATIVE  ANALYSES  ............................................................................................ 28 
10.1 Statistical  Methods  ............................................................................................................................................................ 28 
10.1.1  Endpoint  Analysis  ......................................................................................................................................................................... 28 
10.1.2  Accrual  ............................................................................................................................................................................................... 29 
10.2 Safety  population  ............................................................................................................................................................... 29 
10.3 Metabolic  syndrome population  .................................................................................................................................. 29 
10.4 Secondary  endpoint  population  ................................................................................................................................... 29 
11. Safety  Analysis  ........................................................................................................................................................ 29 
11.1 Oversight and  Monitoring  .............................................................................................................................................. 30 
12. ADVERSE  EVENTS  ................................................................................................................................................... 31 
12.1 Definitions ............................................................................................................................................................................ 31 
12.2 Maintenance of  Safety  Information ............................................................................................................................. 33 
12.2
.1 Product Quality  Complaints  ...................................................................................................................................................... 33 
12.2.2  Reconciliation  of SAEs  ................................................................................................................................................................ . 33 
12.3 Dissemination of Safety Information from Astellas, Inc. to Principal  Investigator  ................................... 33 
12.4 Monitoring of Adverse Events and Period  of Obs ervation  ................................................................................. 33 
13. ADMINISTRATIVE  REQUIREMENTS  ................................................................................................................. 34 
13.1 Data Quality Assurance  ................................................................................................................................................... 34 
13.2 Study  Monitoring  ............................................................................................................................................................... 34 
13.3 Ethical  Considerations  ..................................................................................................................................................... 34 
13.4 Patient Information and  Informed  Consent  ............................................................................................................ 34 
13.5 Patient  Confidentiality  .................................................................................................................................................... 35 
13.6 Investigator  Compliance  ................................................................................................................................................. 35 
13.7 On-site Audits  ..................................................................................................................................................................... 35 
13.8 Investigator and Site Responsibility for  Drug  Accountability  ........................................................................... 35 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
7 of 46   
 13.9 Closure of  the Study  .......................................................................................................................................................... 35 
13.10  Record  Retention  ............................................................................................................................................................ 35 
14. USE  OF INFORMATION  .......................................................................................................................................... 36 
15. REFERENCES ............................................................................................................................................................. 37 
16. APPENDICES  ............................................................................................................................................................. 41 
16.1 Eastern Cooperative Oncology Group (ECOG) Scale for  Performance  Status  .............................................. 41 
16.2 Correlative lab sample collection  ................................................................................................................................ 42 
16.3 Short Physical  Performance  Battery  .......................................................................................................................... 42 
16.4 FACT -P questionnaire  ...................................................................................................................................................... 43 
16.5 SHIM  questionnaire  .......................................................................................................................................................... 46 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
8 of 46   
 LIST OF ABBREVIATIONS AND GLOSSARY OF TERMS  
 
Abbreviation  Term  
ADT  Androgen deprivation therapy 
AE Adverse event  
AUC  Area under the plasma concentration versus time curve  
AUC 0-inf Area under the plasma concentration versus time curve zero to infinity  
CRPC  Castrate resistant prostate cancer 
CBC  Complete blood count  
CI Confidence interval  
hs-CRP  C-reactive protein  
CrCL  Creatinine clearance  
CL/F  Apparent oral clearance  
Cmax Maximum plasma concentration  
CT Computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CYP  Cytochrome P 450 
DDI Drug -drug interaction  
DNA  Deoxyribonucleic acid  
DXA  Dual -energy x -ray absorptiometry scan  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
EOS  End of study  
FACT -P Functional assessment of cancer therapy -prostate  
FDA  Food and Drug Administration  
FPG Fasting plasma glucose  
FSH Follicle stimulating hormone  
GABA  Gamma -aminobutyric acid  
GnRH  Gonadotropin releasing hormone  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practices  
HDL  High density lipoprotein  
HIPAA  Health insurance portability and accountability act  
HR Hazard ratio  
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
9 of 46   
  
 
Abbreviation  Term  
IB Investigator’s Brochure  
ICF Informed Consent Form 
ICH International Conference on Harmonisation 
IEC Independent Ethics Committee 
IND Investigational new drug  
IRB Institutional Review Board  
IU International units 
LDL  Low density lipoprotein 
LH Leutinizing hormone 
LHRH  Leutinizing hormone releasing hormone 
MedDRA  Medical Dictionary for Regulatory Activities  
MTD  Maximum tolerated dose 
NCI National Cancer Institute  
NCI CTCAE  National Cancer Institute Common  Terminology Criteria for     Adverse 
NYHA  New York Heart Association  
PI Principal investigator  
PD Progressive disease  
PFS Progression- free survival  
PSA Prostate specific antigen  
PCWG2  Prostate Cancer Working Group 2 
QOL  Quality of life  
RECIST  Response Evaluation Criteria in Solid Tumors 
SAE  Serious adverse event  
SPPB  Short physical performance battery 
SRE Skeletal related event  
SUSAR  Serious Unexpected Suspect Adverse Reaction  
SHIM  Sexual Health Inventory in Men 
T1/2 Terminal half life  
UCH -North  University of Colorado Health – Poudre Valley Hospital  
ULN Upper limit of the normal range  
V/F Volume of distribution 
WHO  World Health Organization  
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
10 of 46   
  
 
1. BACKGROUND AND STUDY  RATIONALE  
 
1.1 Prostate  cancer 
Prostate  cancer  is the most  common non-cutaneous cancer  in men in the United  States,  and the second 
leading cause of cancer death in US men1. As many as three- quarters of prostate cancer patients 
present with localized disease yet a good proportion have recurrent or metastatic disease requiring 
systemic treatment with androgen deprivation therapy  (ADT).  
 
1.2 Androgen deprivation therapy and metabol ic syndrome  
While many new agents have been developed for the treatment of prostate cancer, these focus on 
treatment in the metastatic, castrate- resistant setting. Patients requiring systemic therapy for prostate 
cancer continue to be initially treated wit h traditional gonadotropin hormone analogues, despite 
advances in therapeutic development. The treatment is very effective with survival results mainly 
impacted by disease state at initiation. The average time from biochemical recurrence, or prostate 
speci fic antigen (PSA) relapse, to development of metastatic disease is approximately 8 years 2 and 
survival for patients with metastatic disease on ADT is approximately 30 months. The median time 
of response for patients with biochemically relapsed disease treated with ADT is 10.8 months 3. 
Thereafter,  patients  remain  on ADT  in combination with other therapies  for the  duration of their anti- 
cancer therapy, which may be years. Men treated with ADT ex perience long -term adverse effects 
such as fatigue, loss of muscle mass (i.e. sarcopenia), loss of bone density, increased adiposity, 
development of metabolic syndrome, depression, sexual dysfunction and poor quality of life (QOL)4- 
13. Men treated  with ADT  had lower  levels of self-reported  physical function and QOL  in comparison 
to age-matched  controls 8,10,14 -17. These effects are profound for any patients  but may be felt to a larger 
degree in  the standard  older patient population afflicted  with prostate  cancer,  already  dealing with the 
changes of decreasing functional reserve.  
 
1.3 Metabolic syndrome 
One of the long term sequelae of ADT is the development of metabolic syndrome. While many 
definitions exist, “metabolic syndrome” broadly encompasses reduced insulin sensitivity and 
increasing body mass. The syndrome itself imposes a higher risk of cardiovascular disease and 
diabetes which subsequently impact mortality risk 18. Metabolic syndrome is a common health 
problem in the United States with a distant evaluation of the prevalence estimated at over 40% for persons over the age of 60 with more recent up dates suggesting that the incidence is increasing 
19. 
This is the same age group most likely to be affected by prostate cancer. A long term hypogonadal 
state, such as is induced by prostate cancer therapy, has been shown to independently predict the 
development of metabolic syndrome, and patients with metabolic syndrome have a 3 times greater risk of death  from  cardiovascular disease  than  healthy counterparts 
20,21. There are data supporting the 
role of hypogonadism in independently increasing the risk of many of the components of metabolic 
syndrome such as dyslipidemia, hypertension, alterations in body mass and glucose intolerance, and 
that these parameters may  change as early as 3 -6 months after the initiation of therapy 7,22-25. 
Population- based  analyses  have  shown a higher incidence of diabetes  and coronary disease  in patients 
treated with ADT 26,27. Cross sectional studies have shown that men with prostate cancer treated with 
ADT  are twice  as likely  to meet  the criteria  for metabolic  syndrome in comparison  to matched  prostate 
cancer patients or healthy controls7. Unlike many cancer treatments, patients remain on ADT for 
years,  allowing  for the development of long-term sequelae,  which  impact  a patient’s global health  and 
quality of life during survivorship  and may contribute to overall  mortality  in equal parts  as the cancer.  
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
11 of 46   
  
1.4 Rationale for study  design  
Improved understanding of the biology of prostate cancer has allowed for the development of agents, 
which more effectively manipulate the androgen axis even under castrate conditions. Not only 
reduction in circulating testosterone, but also improved blockade of the androgen receptor has led to 
an improvement in survival  for patients  with metastatic castrate resistant  prostate cancer  (CRPC).  The 
development of a new generation of agents, such as enzalutamide, that preserve circulating 
testosterone levels while acting on the androgen receptor, provide new therapeutic opportunities for 
an active  single  agent with  the potential for  a reduction of the  long term effects  associated  with  ADT. 
Single agent data of enzalutamide reveals an excellent PSA response and tolerance profile28 
Preservation of these hormone levels may delay the adverse effects associated with long term ADT 
that contribute to development of metabolic  syndrome. 
 
The influence of the adverse events associated with newer agents on a patient’s QOL is increasingly 
used to guide cancer care 29, and under standing the comparative effectiveness of agents is important. 
Men with prostate cancer have higher rates of noncancerous mortality than men in the general 
population, perhaps due to the contribution of the hypogonadal state in worsening common causes of 
death such as heart disease and diabetes. The clustering of cardiovascular risk factors, which occurs 
with ADT, may not be found in patients treated with enzalutamide due to its preservation of  systemic 
testosterone levels. There has not been a longitudinal  analysis of the development of metabolic 
syndrome in patients  on ADT,  nor a structured  evaluation of the development of metabolic syndrome, 
or metabolic changes in patients treated with enzalutamide. This protocol will evaluate the effect of 
androgen blockade via enzalutamide versus traditional ADT on development of metabolic syndrome, 
changes in body composition, changes in quality of life, and changes in physical function in patients 
with advanced prostate cancer.  
 
1.5 Enzalutamide  
Enzalutamide is a non- steroidal anti-androgen that blocks the ability of testosterone to signal through 
the androgen receptor. Enzalutamide has no known agonistic properties even when the androgen 
receptor is overexpressed as supported in preclinical models of CRPC. Enzalutamide is currently 
approved by the FDA for treatment of men with metastatic prostate cancer that have previously been 
treated with docetaxel chemotherapy. In the AFFIRM trial, which led to this approval, patients 
received enzalutamide 160mg/day orally or placebo 30. The study showed a survival advantage for 
patients treated with enzalutamide of 18.4 months in comparison to 13.6- months (hazard ratio (HR) 
0.631 [95% CI: 0.529-0.752], p< 0.0001).  Other endpoints of radiographic progres sion free survival  
(PFS),  8.3 versus  (vs) 2.9 months; hazard  ratio (HR)  0.40, p< 0.001 and PSA response 54% vs 2%, p< 
0.001were also significantly improved in those receiving enzalutamide. The AFFIRM trial also 
supported an improved QOL  in the enzalutamide treated  group as well as improvement in time to first 
skeletal -related event (SRE) (16.7 vs 13.3 months; HR 0.69, p< 0.001). In addition, the PREVAIL 
trial is studying enzalutamide versus placebo in men with metastatic castrate resistant prostate cancer that have not yet been treated with chemotherapy and has reported promising results that will likely 
lead to its approval  
31. 
 
Ongoing studies of enzalutamide are evaluating its efficacy earlier in the treatment spectrum. The Phase II, STRIVE trial is evaluating the efficacy of enzalutamide for patients that may have castrate resistant disease with metastatic and non -metastatic CRPC ([STUDY_ID_REMOVED]). In addition, there was a 
relatively small phase II trial evaluating the use of enzalutamide prior to the initiation of traditional 
testosterone- lowering agents 
32. This single agent trial was conducted in 67 men without previous 
exposure to ADT with a primary endpoint of PSA response defined as an 80% decline from baseline. 
Monotherapy with enzalutamide was highly effective, with a median PSA decrease of    99.6% seen,  
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
12 of 46   
  
and 92.5% of patients  achieving the primary  endpoint at week  25. The trial enrolled  patients  with and 
without metastatic disease at  baseline.  
 
In the randomized clinical  trial in patients  with metastatic  castration -resistant  prostate  cancer  who had 
previously received  docetaxel,  1200 patients were enrolled. The most  common adverse drug reactions 
(≥ 5%) reported in patients receiving enzalutamide in the randomized clinical trial were 
asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral edema, musculoskeletal pain, 
headache, upper respiratory infection, muscular weakness, dizziness, insomnia, lower respiratory 
infection, spinal cord compression and cauda equina syndrome, hematuria, paresthesia, anxiety, and 
hypertension 33. Severe, grade >3 adverse events, were reported in 47% patients rec eiving 
enzalutamide and 53% of patients receiving placebo. The most common adverse reaction leading to 
treatment discontinuation in the enzalutamide treated group was seizure, which occurred in 0.9% of 
the enzalutamide- treated  patients  compared  to none (0%) of the placebo- treated  patients.  In the Phase 
III trial, 7 of 800 patients treated with enzalutamide experienced a seizure in comparison to 0 events in the placebo arm. The seizures occurred days 31 -603 after drug initiation. No further seizures 
occurred  after patients discontinued enzalutamide. Patients were never readministered enzalutamide 
while on study, and patients with a history of seizure have been excluded in additional studies. It is thought that the mechanism of seizure may be the inhibition of  the GABA- gated chloride channel. It 
is suggested that enzalutamide may lower the seizure threshold but not directly contribute to these events. This trial will exclude patients with a predisposition to seizure, as the exclusion of this subset 
of patients should not have  a known impact  on altering  the incidence of metabolic syndrome. Another 
notable adverse event associated with the enzalutamide treatment arm is fall and fall -related injuries. 
This occurred in 4.6% of patients enrolled in the randomized trial and assigned to the enzalutamide 
treatment group in comparison to 1.3% of patients treated with placebo. The mechanism of fall is not 
clear.  Fall -related injuries are described as joint injuries, non -pathologic fractures, and hematomas.  
 
Very few la boratory abnormalities were seen in patients treated with enzalutamide. Neutropenia of 
all grades occurred in 15% of patients on enzalutamide (1% Grade 3- 4). The incidence of 
thrombocytopenia was similar in the treatment and placebo arms (0.5% on enzalutamide v 1% on placebo). Elevation in transaminases occurred in 10% of patients on enzalutamide (0.3% Grade 3- 4) 
and 18% of patients on placebo (0.5% Grade 3-4), with elevations in bilirubin occurring in 3% v 2 % on placebo. 
 
1.6 Androgen deprivation therapy  
Standard androgen deprivation therapy is a broad term encompassing any agent, or method, which 
invokes a castrate state for the treatment of prostate cancer. Medical therapy generally includes a gonadotropin releasing hormone (GnRH) analogue (agonist or antagonist) with a lowering of 
testosterone to castrate levels as the primary result of treatment. The agonists bind to the GnRH receptors in the pituitary  to alter release  of luteinizing  and follicle  stimulating  hormones (LH and FSH) 
and eventually alter the fe edback loop. A GnRH antagonist suppresses testosterone while avoiding 
the initial flare in testosterone seen with the administration of GnRH agonist. Examples of currently 
available formulations include: degarelix, goserelin, leuprolide, triptorelin, and histerelin. Surgical 
castration  by means of an orchiectomy also reduces  overall  testosterone  production. Hormone therapy 
is palliative in nature but has been shown to have a significant effect on the morbidity and mortality 
of prostate cancer. Notable side effects include sexual dysfunction, osteoporosis, sarcopenic obesity, 
increase in cardiovascular risk factors an d diabetes, vasomotor symptoms, fatigue and alterations in 
cognition. 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
13 of 46   
  
1.7 Nonclinical Experience  
1.7.1  Drug Metabolism and Pharmacokinetics  
Enzalutamide alters the functioning of the androgen receptor -signaling pathway. Enzalutamide has 
been shown to competitively inhibit androgen binding to androgen receptors and to inhibit the 
translocation  of the receptor  to the nucleus and subsequent DNA binding. The phase I, first-in-human 
trial of enzalutamide (or MDV3100) enrolled 140 patients with CRPC 34. Dosing ranged from 30 to 
600 milligrams (mg)/day with the maximum tolerated dose (MTD) determined as 240 mg orally per day.  The recommended phase II dose was 160 mg/day. 
 
The major active metabolite of enzalutamide is N -desmethyl enzalutamide. The pharmacokinetics of 
enzalutamide and this metabolite  have been  evaluated  in healthy male  volunteers or men with castrate- 
resistant metastatic prostate cancer 
33. A linear two -compartment model with first -order absorption 
adequately described. Following oral administration, the median time to reach maximum plasma enzalutamide concentrations (C
max) is 1 hour. The mean steady state C max values are 16.6 μg/mL for 
enzalutamide and 12.7 μg/mL for N-desmethyl enzalutamide.  The mean predose trough values    are 
11.4 μg/mL  and 13.0 μg/mL,  respectively.  With  the approved dosing schedule,  steady  state is reached 
in 28 days due to the long half -life ( t 1/2) of 5.8 days. At s teady state, enzalutamide showed 
approximately dose proportional pharmacokinetics. The mean apparent volume of distribution (V/F) of enzalutamide in patients after a single oral dose is 110 L. Enzalutamide is 98% bound to plasma 
proteins.  N- desmethyl enzalutamide is 95% bound to plasma proteins. 
 
Plasma samples were analyzed after a single oral administration of 160mg of carbon -labeled 
enzalutamide. Enzalutamide, N -desmethyl enzalutamide, and an inactive carboxylic acid metabolite 
accounted  for 30%, 49%, and 10%, respectively,  of the  total AUC.  Based  on in vivo and in vitro  data, 
CYP2C8 is primarily responsible for the formation of N -desmethyl enzalutamide, but in vitro data 
suggests the CYP3A4 is partially responsible for  metabolism.  
 
Enzalutamide is prim arily eliminated by hepatic metabolism. The majority of elimination is through 
the urine (71% from one study) with 14% through feces. The mean apparent clearance (CL/F) of enzalutamide in patients after a single oral dose is 0.56 L/hour.  
 
Based on limited data, the apparent clearance of enzalutamide is similar in patients with pre- existing 
mild and moderate renal impairment (CrCL 30 to < 90 mL/minute) compared to patients and 
volunteers with normal renal function. There are insufficient data to describe the  potential effect of 
more severely impaired renal function on the clearance of enzalutamide. Hepatic function abnormalities of mild or moderate  grade  do not affect  the area under the curve  (AUC)  of enzalutamide 
or its active  metabolite.  
 
1.8 Toxicology 
1.8.1  Drug -Drug Interaction Risk  Assessment  
In a drug-drug interaction trial in healthy volunteers, a single 160 mg oral dose of enzalutamide was administered alone or after multiple oral doses of a strong CYP2C8 inhibitor and the AUC was increased 2.2 tim es with minimal effect on C
max. When administered with a single dose of a strong 
CYP3A4 inhibitor, the AUC 0-inf increased by 1.3 times 33. 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
14 of 46   
  
2. STUDY  OBJECTIVES  
 
2.1 Primary  Objectives  
To determine the incidence of metabolic syndrome within 12 months, as defined by the Adult 
Treatment  Panel  III, in patients treated  with enzalutamide compared  to standard  androgen deprivation 
therapy. 
 
2.2 Secondary  Objectives  
In patients treated with enzalutamide versus traditional ADT:  
 To determine the incidence of metabolic syndrome within 6 months, as defined by the Adult 
Treatment Panel III, in patients treated with enzalutamide compared to standard androgen deprivation therapy 
 To assess bone health, as measured by a DXA  scanner  
 To assess body composition (sarcopenic obesity), as measured  by measurements of fat on CT 
 To assess QOL, as measured by the FACT -P and  SHIM  
 To assess time to PSA progression and time to radiographic progression. Progression will be defined as lack of clinical  benefit  in the setting  of either  rising  PSA,  growth  of visceral  or soft 
tissue metastasis, or development of new bone metastasis as defined per protocol  
 To assess the incidence of developing individual risk factors,  or components, which  comprise 
metabolic syndrome  
 To assess the change in hs- CRP as a marker of  inflammation  
 To assess the safety and tolerance of enzalutamide or  ADT  
 To assess the change in physical function as measured by the Short Physical Performance Battery  (SPPB)  
 
3. STUDY  ENDPOINTS  
 
3.1 Primary  Endpoints  
Incidence of metabolic syndrome within 12 months as defined by the ATP III, in patients treated with enzalutamide versus patients treated with standard testosterone- lowering ADT.  
 
3.2 Secondary  Endpoints  
 Incidence of metabolic syndrome within 6 months, as defined by the ATP III, in patients 
treated with enzalutamide versus patients treated with standard testosterone-lowering ADT  
 Change in bone density, as measured by a DXA  scanner  
 Change in bone turnover as measured by bone- specific alkaline phosphatase and N - 
telopeptide  
 Change in body composition (fat distribution as measured on CT) 
 Change in QOL, as measured by the FACT -P and  SHIM  
 Time to PSA progression and time to radiographic progression. Progression will be defined 
as lack of clinical benefit in the setting of either rising PSA, growth of visceral or soft tissue 
metastasis, or development of new bone metastasis as defined per  protocol  
 Incidence of developing individual risk factors, or components, which comprise metabolic 
syndrome  
 Change in inflammatory markers as measured by serum  hs-CRP  
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
15 of 46   
  
 Safety and tolerability as assessed by regular recording of toxicities via physical exam and 
laboratory analysis using the CTC AE v4.1 guidelines  
 Change in physical function as measured by the Short Physical Performance Battery  
 
4. STUDY  DESIGN  
 
4.1 Overview of Study  Design  
This study is a multi -center, open label, randomized, phase II trial of the incidence of metabolic 
syndrome within 12 months in patients treated with enzalutamide in comparison with androgen deprivation therapy for treatment of advanced prostate cancer. This will include patients with 
biochemically recurrent disease, metastatic disease, and patients offered ADT as primary therapy if 
they are not candidates for local therapy. Fifty -six patients will be 1:1 randomized to one of two 
treatment  arms  with metastasis  as a stratification  factor.  Patients will be treated  for a 12-month period 
continuously and assessed for the development of metabolic syndrome at 3-month intervals.  
 
Treatment  will be administered  for a 12-month period. Enzalutamide will be taken  orally  on each day 
of the cycle. Androgen deprivation therapy will be administered according to standard of care; 
however, there will be no intermittent dosing of this treatment. Acceptable forms of ADT must result in castrate levels of testosterone (<50ng/dL), and may include: leuprolide, goserelin, histerelin, triptorelin,  degarelix, and surgical  castration.  Toxicity  will be evaluated  according to National Cancer 
Institute  Common Terminology Criteria  for Adverse  Events  (NCI  CTCAE),  Version  4.1 
35. Metabolic 
syndrome will be diagnosed by assessing a patient’s blood pressure, waist circumference, fasting glucose,  high density lipoprotein (HDL),  and triglyceride  level  and determined  according to the Adult 
Treatment Panel III criteria  
36. 
 
Analysis of bone turnover  will include measurement  of urinary N- telopeptide  and serum  bone- specific 
alkaline phosphatase. A dual -energy x -ray absorptiometry scan (DXA) will also be performed at 
enrollment, month 3 and EOT. This scan will provide information on bone density changes induced 
by treatment.  
 
Quality of life questionnaires will be administered at each study visit. Physical function changes will be assessed via the Short Physical Performance Battery; the SPPB incorporates 3 validated portions 
to assess a patient’s balance and mobility. Changes in systemic inflammation will be assessed via 
circulating hs -CRP levels. Additional collection of complete blood counts and chemistries will 
provide safety information.  Thi s testing will occur in the clinic setting every 3 months as well.  
 
Adverse events (AEs) will be assessed; and laboratory values, vital signs, and physical exam will be obtained in order to evaluate the development of metabolic syndrome in patients treated with either 
enzalutamide or standard androgen deprivation therapy. In addition, we will obtain a PSA every 3 
months and radiographic  imaging  at baseline,  6 months, and 12 months. Patients  may remain  on study 
as long as they are deriving clinical benefit, until there is clear progression of disease (per protocol), 
unacceptable toxicity, or withdrawal of consent. 
 
4.2 Duration of Study  
Patients will continue therapy until disease progression, development of unacceptable toxicities, non- compliance, intercurrent illness  that prevents treatment  continuation, withdrawal  of consent,  or change 
in subject condition that render the subject unacceptable for further treatment.  If a patient   develops  
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
16 of 46   
  
metabolic syndrome, but the patient has at least stable disease and ongoing clinical benefit, then the 
patient may be allowed to continue on their assigned treatment. The End of Study (9) visit will occur 
within  30 days after  the last dose of study drug, or prior  to the start of subsequent  anti-cancer  therapy. 
Patients will be assessed for metabolic syndrome over a 12 -month period of treatment, as this allows 
adequate time in which to see the emergence of the metabolic syndrome parameters as well as time for patients to derive a potential clinical benefit from t he respective treatment agent. Patients with 
continued clinical benefit beyond the 12- month endpoint will have the option of remaining on their 
current therapy with  additional follow  up visits  every  3 months for safety  and tolerability  assessment. 
Patients  receiving  enzalutamide will no longer receive this as a study medication  beyond  the 12-month 
time point but may potentially obtain the medication through standard prescribing methods. It is estimated this trial will take 36 months to  complete.  
 
4.3 Overview of treatment  
During the trial, patients will be assigned to treatment with either enzalutamide or standard of care ADT. For patients randomized to the ADT arm, the choice of type of ADT will be at the discretion  
of the treating provider. Patients that are  in the enzalutamide arm may not also be treated with ADT. 
In addition, patients  on the ADT  arm may not also be treated  with an androgen -receptor  blocker. Anti- 
androgen therapy may be administered as a single agent <14 days prior to and 14 days following 
medical  castration  with a GnRH agonist in order  to cover  the potential testosterone  surge.  Intermittent 
dosing of ADT is not acceptable. Enzalutamide will be dosed at the approved dose of 160mg orally daily. ADT will be administered according to the standard prescribing information for the agent. All 
subjects should also take at least 1000mg of calcium and 800 International Units (IU) of vitamin D. 
This treatment will allow protection against bone density loss caused by metastasis or ADT. All 
subjects will receive this treatment to avoid confounding data, as it is a non -toxic, non- prescription 
supplement. 
 
4.4 Criteria for Dose Administration  
4.4.1 Study Drug  Administration  
All protocol -specific criteria for administration of study drug must be met and documente d prior to 
drug administration. Enzalutamide or ADT will be administered only to eligible patients under the 
supervision of the investigator or identified sub- investigator(s).  
 
Patients should be instructed to take their study medication at approximately t he same time each day. 
Enzalutamide can be taken with or without food, patients must swallow capsules whole without chewing, opening or dissolving the capsule.  If a patient  misses  a dose, then they should take it as soon 
as they remember.  If they forget an entire  day’s  dose,  they should take their normal  dose the next day. 
They should not take more than their prescribed dose per day. 
 
For any depot-injections of ADT,  the site of injection  and name  of the agent  will be recorded.  Patients 
on depot- injections may only be treated with formulations given every 4, 8, or 12 weeks.  
 
4.4.2 Clinical Benefit  
Continuation on the trial is dependent on toxicities, as well as evidence of clinical benefit. Patients 
must  not have  evidence of radiographic or PSA disease  progression as per protocol section  7. Efficacy 
assessments will be performed via provider assessment. Imaging studies will be obtained every 6 
months, or sooner at the discretion of the treating provider.         PSA values will be assessed every 3  
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
17 of 46   
  
months, or sooner at the discretion of the treating provider. Patients with progressive disease per 
section 7 will be ineligible to receive further study treatment.  
 
4.5 Dose Modification  Guidelines  
Patients will be assessed for toxicities at each study visit, every 3 months. Patients may be evaluated 
more frequently at the discretion of the treating provider. Toxicities are to be assessed according to 
the NCI CTCAE, version 4.1. Each AE should be assessed for potential contribution by the study 
drug. If a patien t experiences a grade >3 toxicity  on enzalutamide or an intolerable  side effect,  withhold 
dosing for one week or until symptoms improve to grade <2. Dosing may resume at the same, or a 
reduced dose, (per treating physician discretion) for a maximum dose reduction to 80mg daily. Once 
a dose reduction has occurred, the patient may not re- escalate to a higher dose. 
 
There are no dose modifications for ADT. As stated, this therapy must be dosed continuously and may not be given on an intermittent basis. 
 
4.6 Study specific biomarker  collection 
Plasma samples will be obtained and stored for future correlative analysis regarding potential identified biomarkers important in the development of metabolic syndrome or prostate cancer 
progression. Approximately 3 7mL tube s of blood will be drawn. De -identified tubes will be 
processed and stored for future analysis. See lab manual for processing instructions. 
 
5. STUDY POPULATION  
 
5.1 Inclusion  Criteria  
Each patient must meet all of the following inclusion criteria to be enrolled in the study:  
1. Histologically or cytologically proven adenocarcinoma of the prostate. If pathology is unavailable, the PI may also make a determination of prostate cancer based on unequivocal 
clinic  data.
 
2. Patients with advanced prostate cancer suitable for systemic treatment defined as: having 
metastatic disease, a biochemical relapse after primary therapy, or patients in whom primary 
therapy is not appropriate  or feasible.  Patients  without metastatic  disease will need evaluation 
for local therapy and deemed inappropriate or have refused this treatment option 
3. ECOG 0-2 
4. Age > 18 years old 
5. Must use a condom if having sex with a pregnant woman  
6. A male patient and his female partner who is of childbearing potential must use 2 acceptable 
methods of birth control (one of which must include a condom as a barrier method of 
contraception) starting at screening and continuing throughout the study period and for 3 months after final study drug  administration  
7. Life expectancy estimated at >12  months 
8. Ability to understand and willingness to provide written informed consent document 
 
5.2 Exclusion  Criteria  
The following are criteria for exclusion from participating in the study:  
1. A history of androgen deprivation therapy. 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
18 of 46   
  
a. Patients receiving hormonal therapy in the adjuvant and/or neoadjuvant setting 
must have discontinued therapy at least 6 months prior to day 1 of treatment  
b. AND have a serum testosterone level >50ng/dL 
c. AND cannot have received more than 18 months of previous ADT.  
2. A history of orchiectomy  
3. Previous an drogen blockade (e.g. antiandrogens) given for greater than 2 weeks in the 
last 3 months. Anti-androgens used during the initiation of ADT to avoid a flare 
phenomenon are acceptable for up to 4 weeks.  
4. Patients already meeting the criteria for metabolic syn drome as defined by the Adult 
Treatment Panel III Criteria which requires 3/5 parameters below.. Patients with 2 of  the 
parameters at baseline will be allowed enrollment provided that one of those risk factors is hypertension (≥130/≥85 mm Hg). 
a. Abdominal obesity, defined as a waist circumference >102 cm (>40  in) 
b. Serum triglycerides ≥150 mg/dL (1.7 mmol/L) or drug treatment for elevated 
triglycerides  
c. Serum HDL cholesterol <40 mg/dL (1 mmol/L) or drug treatment for low HDL  
d. Blood pressure ≥130/≥85 mmHg or drug treatment for elevated blood  pressure  
e. Fasting plasma glucose (FPG) ≥100 mg/dL (5.6 mmol/L) or drug treatment for 
elevated blood glucose  
5. Baseline hypogonadism as defined as a testosterone <50  ng/dL  
6. PSA <0.5ng/dL 
7. Serum Vitamin D 25, OH <12 ng/mL  
8. Active Hepat itis C  virus  
9. Use of corticosteroids as defined by a daily dose of prednisone (or equivalent) of 5mg or 
greater for more than 1 month continuously within 3 months of screening  
10. Corrected calcium >10.6 mg/dL  
11. Absolute neutrophil count <1500/uL; platelet count <100, 000/uL, hemoglobin <9g/dL 
12. Total bilirubin >1.5xULN (unless documented Gilbert’s); alanine aminotransferase or 
aspartate aminotransferase > 2.5xULN 
13. Creatinine >2mg/dL  
14. Clinically significant cardiovascular disease as evidenced by: Myocardial infarction within 6 months of screening; uncontrolled angina within 3 months of screening; New 
York Heart Association (NYHA) class 3 or 4 congestive heart failure; clinically 
significant ventricular arrhythmia; Mobitz II/2
nd degree/or 3rd  degree heart block without 
a pacemaker in place;  uncontrolled  HTN  (systolic  >180mmHg  or diastolic  >105mmHg at 
screening)  
15. Previous exposure to enzalutamide  
16. Use of an investigational therapeutic within 30  days 
17. History of gastrointestinal disorders (medical disorders or extensive surgery) that may 
interfere with the absorption of the study agent  
18. Known or suspected brain metastasis or active leptomeningeal  disease  
19. History of seizure or any condition that may predispose to seizure (e.g., prior cortical 
stroke, significant brain trauma) at any time in the past. Also, history of loss of consciousness or transient ischemic attack within 12 months of Day 1 visit 
20. Have any condition that, in the opinion of the investigator, would compromise the well- being of the  subject  or the study or prevent  the subject  from  meeting  or performing study 
requirements  
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
19 of 46   
  
6. STUDY PROCEDURES AND ASSESSMENTS  
The schedule of assessments is summarized in Table 1  
6.1 Informed  Consent  
Enrollment in the study requires  that all inclusion  and exclusion criteria  have  been  met. A patient  may 
be enrolled into the study when the written informed consent has been obtained and the patient’s 
eligibility per all inclusion and exclusion criteria has been  confirmed. 
 
6.2 Randomization 
Randomization will occur using the GraphPad QuickCalcs randomization service. 
 
6.3 Study  Visits  
Patients will be evaluated at scheduled visits over the following study periods: Screening, Treatment, 
and end of study (EOS). Tests and procedures should be performed on schedule for all visits during 
Cycle 1. During all subsequent cycles, occasional changes are allowable (± 5 days) with permission 
for holidays and other administrative reasons. If extenuating cir cumstances prevent a patient from 
completing a scheduled procedure or assessment within this time, the patient may continue the study 
only with the permission of the Principal Investigator (PI). All EOS evaluations should occur within 30 days after the last dose of study drug, or prior to the start of subsequent anti- cancer therapy.  
 
6.3.1 Physical  Examination  
A complete physical examination will be performed before dosing on Day 1 of each cycle and at the 
end of treatment. Vital signs (temperature, blood pressure, pulse rate, respiratory rate, weight, waist 
circumference) will be performed at each visit. ECOG performance status will be evaluated at day 1 of each cycle and end of study.  Clinically significant AEs will be captured as well.  
 
6.3.2 Schedule of Events 
Screening/Baseline Day -21 - 0 
 Informed consent and HIPAA release  
 Study eligibility per inclusion/exclusion  criteria  
 Medical history/baseline  conditions  
 Physical  examination  
 Vital signs, including height and weight, waist circumference  
 ECOG performance status 
 Blood samples for hematology, comprehensive metabolic panel (fasting), lipid profile  
 Serum  Testosterone  
 Serum  PSA 
 25-OH Vitamin  D 
 CT scan and assessment of tumor burden, may use imaging study within 28 days of day 1  
 Bone scan, may use imaging study within 28 days of day 1  
 Collection of concomitant medications  
 Collection of adverse events 
 
Month 1 Day 1 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
20 of 46   
  
 Physical  examination  
 Vital signs, including weight and waist circumference  
 ECOG performance status  
 Blood samples for CBC,  Comprehensive metabolic panel  (fasting),  PSA,  N-telopeptide,  bone 
specific alkaline phosphatase, estradiol,  hs-CRP  
 Optional tubes of blood for future biomarker testing  
 FACT -P, SHIM  completed  
 DXA scan (+/ -14 Days of Day 1 Dosing); note that there must be a 14 
day separation of bone scan and a DXA  scan 
 Short Physical Performance Battery  
 Collection of concomitant medications  
 Collection of adverse events 
 Dosing of medication, or documentation of continued dosing  
 Verification of calcium/vitamin D  administration  
 
Month 2 Day 1 +/- 5 days 
 Physical  examination  
 Vital signs, including weight and waist circumference  
 ECOG performance status 
 Blood samples for CBC, Comprehensive metabolic panel (fasting), PSA, testosterone  
 Collection of concomitant medications  
 Collection of adverse events 
 Dosing of medication, or documentation of continued dosing  
 Verification of calcium/vitamin D  administration  
 
Month 4 Day 1+/- 5 days 
 Physical  examination  
 Vital signs, including weight and waist circumference  
 ECOG performance status 
 Blood samples for CBC, Comprehensive metabolic panel (fasting), testosterone, PSA, N- 
telopeptide, bone specific alkaline phosphatase, lipid profile, estradiol, hs-CRP  
 Optional tube of blood for future biomarker testing  
 FACT -P, SHIM  completed  
 DXA scan (+/-14 Days of Day 1 Dosing); note that there must be a 14 
day separation of bone scan and a DXA  scan 
 Short Physical Performance Battery  
 Collection of concomitant medications  
 Collection of adverse events 
 Dosing of medication, or documentation of continued dosing  
 Verification of calcium/vitamin D  administration  
 
Month 7 Day 1+/- 5 days 
 Physical  examination  
 Vital signs, including weight and waist circumference  
 ECOG performance status 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
21 of 46   
  
 Blood samples for CBC, Comprehensive metabolic panel (fasting), testosterone, PSA, N - 
telopeptide, bone specific alkaline phosphatase, lipid profile, estradiol, hs- CRP, 25-OH 
Vitamin  D 
 Optional tubes of blood for future biomarker testing  
 FACT -P, SHIM  compl eted 
 CT scan and assessment of tumor burden +/- 5 days 
 Bone scan +/- 5 days 
 Short Physical Performance Battery  
 Collection of concomitant medications  
 Collection of adverse events 
 Dosing of medication, or documentation of continued dosing  
 Verification of cal cium/vitamin D  administration  
 
Month 10 Day 1+/- 5 days 
 Physical  examination  
 Vital signs, including weight and waist circumference  
 ECOG performance status 
 Blood samples for CBC, Comprehensive metabolic panel (fasting), testosterone, PSA, N- 
telopeptide, bone specific alkaline phosphatase, lipid profile, estradiol, hs- CRP  
 Optional tube of blood for future biomarker testing  
 FACT -P, SHIM  completed  
 Short Physical Performance Battery  
 Collection of concomitant medications  
 Collection of adverse events 
 Dosing of medication, or documentation of continued dosing  
 Verification of calcium/vitamin D  administration  
 
Month 13 Day 1 or End of Treatment (+/ - 5 days) 
 Physical  examination  
 Vital signs, including weight and waist circumference  
 ECOG performance status 
 Blood samples for CBC, Comprehensive metabolic panel (fasting), testosterone, PSA, N - 
telopeptide, bone specific alkaline phosphatase, lipid profile, estradiol, hs- CRP, 25-OH 
Vitamin  D 
 Optional tubes of blood for future biomarker testing  
 FACT -P, SHIM  compl eted 
 DXA scan (+/-14 Days  of Day 1 Dosing); note that there  must  be a 14 day separation  of bone 
scan and a DXA  scan 
 CT scan and assessment of tumor burden +/- 5 days 
 Bone scan +/- 5 days 
 Short Physical Performance Battery  
 Collection of concomitant medications  
 Collection of adverse events 
 
End of Study (EOS) safety visit  
 Physical  examination  
 Vital signs, including weight and waist circumference  
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
22 of 46   
  
 ECOG performance status 
 Blood samples for CBC, Comprehensive metabolic panel  
 Collection of concomitant  medications  
 Collection of adverse events 
 
7. STUDY  ASSESSMENTS 
 
7.1 Assessment of metabolic syndrome  
The primary endpoint is the determination of the incidence of metabolic syndrome in patients with 
advanced  prostate cancer  treated  with either  enzalutamide or standard ADT.  Metabolic  syndrome will 
be assessed every 3 months and defined by the presence of 3 of the following five traits 36: 
• Abdominal obesity, defined as a waist circumference >102 cm (>40 in) 
• Serum tr iglycerides ≥150 mg/dL (1.7 mmol/L) or drug treatment for elevated 
triglycerides  
• Serum HDL cholesterol <40 mg/dL (1 mmol/L) or drug treatment for low HDL  
• Blood pressure ≥130/≥85 mmHg or drug treatment for elevated blood pressure  
• Fasting plasma glucose (FPG) ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevated 
blood glucose 
 
Patients may continue on treatment even upon development of metabolic syndrome at the discretion 
of the PI.  
 
7.2 Efficacy  Evaluations  
 
7.2.1 PSA  
Patients will be monitored for clinical efficacy while on study. Serum PSA will be obtained every 3 
months. PSA rise is allowable at the discretion of the investigator. However, patients must discontinue treatment  if there  is evidence of  PSA  progression as defined by an increase  in >50% from 
nadir and an absolute increase of at least 2 ng/mL above the nadir, occurring at least 12 weeks after start of therapy that is confirmed by two consecutive increases taken at least 2 weeks apart. The date 
of first recorded increase will serve as the date of  progression. 
 
7.2.2 Radiographic evaluation 
Patients will be removed from study if they have evidence of radiographic disease progression as defined below. Radiographic analysis via CT scan (and/or  MRI),  and bone scan will occur at baseline, 
6 months, and 12 months. For the purposes of this study, investigators should utilize the protocol - 
specified tumor assessment criteria, defined as assessment of evaluable soft tissue disease sites 
according to RECIST v1.1, and/or assessment of bone disease according to the PCWG2 criteria. Soft tissue disease will be assessed on CT (or MRI) and defined by RECIST v1.1. Bone disease will be 
assessed on bone scan and progression will be defined as the development of two or more new bone 
lesions from baseline confirmed with an additional lesion on bone scan 6 weeks later. New bone 
lesions noted after the 6- month radiographic assessment do not require a confirmatory bone scan. 
Increase in intensity of known bone lesions will not constitute progression. The date of progression will be recorded as the date the first scan shows change.  
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
23 of 46   
  
7.3 Body composition  evaluation  
The change in bone health will be assessed via urine N -telopeptide and serum bone specific alkaline 
phosphatase measurements. Bone density will be assessed via a DXA scan. The density of the 
posterior- anterior lumbar spine, total hip, femoral neck, and total body bone mineral density will be 
analyzed. Additional body composition analysis of lean body mass and total body mass will be 
analyzed via cross sectional  CT image analysis. Changes in body composition can be seen as early  as 
3 months in studies  of testosterone  supplementation 39 or ADT  40 causing  an increase  in adipose tissue 
and decrease in lean muscle.  
 
7.4 Quality of life  assessment  
The Functional Assessment of Cancer Therapy – Prostate (FACT -P) questionnaire will provide data 
on how patients  perceive their QOL  while  on enzalutamide  or ADT.  The FACT -P tests five subscales: 
physical,  social,  emotional,  functional wellbeing  and additional concerns specific  to men with prostate 
cancer 41. The FACT -P scales have been widely used to evaluate quality of life in clinical trials for 
prostate cancer  treatments.  Internal consistency  of the FACT -P (version  4) subscales ranges from  0.85 
to 0.89. Concurrent, construct and discriminant validity has been documented (41). The FACT -P will 
be used descriptively. The questionnaire must be administered at each study visit unless the patient 
refuses.  It is permissible  to assist  the patient  with the completion of the questionnaire. The study staff 
must review the questionnaire at each visit in order to ensure that all items were answered. Patients should be given the option to complete any unmarked questions, but it is not required. 
 
The Sexual  Health  Inventory for Men (SHIM)  will also be used to evaluate alterations  in sexual health 
as a result of treatment with enzalutamide or ADT. The SHIM is a scale used widely to assess the 
presence and severity of erectile dysfunction. The scale is used regularly in clinical practice as well 
as in the research setting. The SHIM will be used descriptively. The questionnaire must be 
administered at each study visit unless the patient refuses. It is permissible to assist the patient with 
the completion of the questionnaire. The study staff must review the questionnaire at each visit in order to ensure that all items were answered. Patients should be given the option to complete any 
unmarked ques tions, but it is not  required. 
 
7.5 Physical function  evaluation 
The Short Physical Performance Battery (SPPB) will be used for physical function evaluation. This 
battery of tests evaluates physical function and mobility. The test includes assessment of a pati ent’s 
ability to perform a chair rise, standing balance, and a 8 foot walk. This battery has a clear scoring system  and a validated  score above which  patients  are identified  as at-risk of physical  decline.  Change 
in score of 1 is clinically significant. Th e SPPB will be modified to include a 10- time chair rise. The 
coordinator will record  the time it takes the subject  to perform  both 5 and 10 rises from  the chair.  This 
modification has been made to increase the sensitivity of the exam in identifying small changes in 
function given the generally fit population seen in the clinic.  
 
7.6 Safety  evaluations  
The principal investigator will oversee the care and safety of all subjects enrolled in the trial. Study 
visits
 will include monitoring and recording all adverse  events and serious adverse events; regular 
monitoring of hematology, blood chemistry, hepatic function; regular measurement of vital signs, physical examination including weight and performance status. Safety and tolerability will be 
assessed using the CT CAE v4.1 guidelines.  
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
24 of 46   
  
7.6.1 Adverse  Events  
Monitoring of AEs will be conducted throughout the study.  AEs will be reported from  the date written 
informed consent is obtained and through 30 days post -last dose of study drug. Serious pretreatment 
events and serious adverse events (SAE)  will be reported  to the Astellas,  Inc. designee.  All SAEs  will 
be monitored until they are resolved  or are clearly  determined  to be due to a patient’s  stable  or chronic 
condition or intercurrent illness (es). 
 
7.6.2 Clinical Laboratory Evaluations 
Clinical laboratory evaluations will be performed locally. Chemistry and hematology results must be 
drawn and reviewed within 24 hours prior to each cycle of dosing. 
 
7.7 Concomitant Medication and Therapies 
Concomitant Strong C YP2C8  Inhibitors  
The concomitant use of strong CYP2C8 inhibitors (i.e. gemfibrozil) should be avoided if possible as 
this increases the plasma AUC of enzalutamide and its active metabolite. If patients must be co - 
administered a strong CYP2C8 inhibitor, reduce the enzalutamide dose to 80 mg once daily. The 
enzalutamide dose should be readjusted if the inhibitor is discontinued. 
 
The effects of CYP2C8  inducers on the pharmacokinetics of enzalutamide have  not been  evaluated  in 
vivo. Co-administration of enzalutamide with strong or moderate CYP2C8 inducers (e.g., rifampin) 
may alter the plasma exposure of enzalutamide and should be avoided if possible. 
 
Drugs that Inhibit or Induce CYP3A4  
Co-administration of a strong CYP3A4 inhibitor increased the AUC of enzalutamide and its active 
metabolite by 1.3 times. 
 
Co-administration  of enzalutamide with strong CYP3A4  inducers (e.g., carbamazepine,  phenobarbital, 
phenytoin, rifabutin, rifampin, rifapentine ) may decrease the plasma exposure of enzalutamide and 
should be avoided if possible. Moderate CYP3A4 inducers (e.g., bosentan, efavirenz, etravirine, 
modafinil, nafcillin) and St. John’s Wort may also reduce the plasma exposure of enzalutamide and should be avoided if  possible. 
 
The following medications and procedures are PROHIBITED during the study: 
• Any anti -cancer therapies other than enzalutamide or single agent ADT. Anti -androgens 
used during the initiation of ADT to avoid a flare phenomenon are acceptable for up to 4 weeks.  
• Patients  not on osteoclast  inhibitors  at study enrollment may not begin  this treatment  while 
on trial. 
 
The following medications and procedures are ALLOWED during the study: 
• Any supportive medications to treat the symptoms of enzalutamide or ADT are allowed 
such as agents to manage hot flashes, nausea, diarrhea, or  depression 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
25 of 46   
  
• Palliative  radiotherapy,  for treatment  of the patient’s  malignancy.  Patients with a fracture 
in an area of pre- existing  metastasis  without clear  progression, the patient  may  remain  on 
trial if approved by the PI. 
• Anti-androgens used during the initiation of ADT to avoid a flare phenomenon are 
acceptable for up to 4  weeks.  
 
7.8 Completion of  Study  
Patients will be considered to have completed the study if they (1) have received at least 1 cycle of 
treatment,  AND (2) experienced  progressive  disease OR (3) experienced  unacceptable toxicity.  In the 
absence of progressive  disease  or unacceptable toxicity,  and in the setting  of continued  clinical  benefit, 
patients may be permitted to remain on therapy upon discussion with the PI. Patients wishing to 
continue therapy beyond cycle 12 may continue on their current therapy at the discretion of their 
treating provider.Patients receiving enzalutamide wil l no longer receive this as a study medication 
beyond the 12-month timepoint  but may be able to obtain  the medication through  standard  prescribing 
methods. 
 
Withdrawal of Patients from Study 
Patients  will be informed  that they have  the right  to withdraw from  study treatment  at any time for any 
reason, without prejudice to their medical care. A patient may be withdrawn from study treatment  for 
any of the following reasons:  
• Adverse Event  
• Protocol Violation  
• Radiographic Progressive Disease as defined in section  7.2 
• Serologic progressive disease as defined in section  7.2 
• Symptomatic  Deterioration  
• Study Terminated by the University of Colorado Cancer Center  
• Withdrawal by  Subject  
• Lost to  Follow-up 
• Other  
 
At the time of study drug discontinuation, all study procedures outlined for the EOS visit should be 
completed within 30 days after the last dose of study drug. The primary reason for a patient’s 
withdrawal from the study is to be recorded. 
 
The consequence of withdrawal of consent by a patient will be that n o new information will be 
collected from that patient and added to the existing data or any database. However, every effort will be made to follow all patients for safety.  
 
7.9 Study  Compliance  
Study drug will be dispensed only to eligible patients under the supervision of the investigator or 
identified sub- investigator(s). The appropriate study personnel will maintain records of study drug 
receipt and dispensing, including the following: applicable lot numbers and total drug administered in milligrams. Any di screpancy regarding the dose administered and the reason for the discrepancy 
will be  noted. 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
26 of 46   
  
Patients will receive a sufficient quantity of enzalutamide for each treatment cycle. The study center 
staff will check the returned pill bottles at each study visit to ensure proper compliance with dosing. 
Patients who are not compliant with the dosing schedule may be withdrawn from the study. 
 
8. INVESTIGATIONAL  AGENTS  
 
8.1 Precautions and Restrictions 
Patients should be instructed to consult with the inves tigator before taking any new medications, 
including over -the-counter and herbal products. Patients should be instructed to limit the use of 
alcohol while enrolled in this study.  
 
8.2 Description of Investigational Agents  
8.2.1 Enzalutamide  
Enzalutamide 40 mg capsul es are white to off -white oblong soft gelatin capsules imprinted in black 
ink with MDV.  Enzalutamide is provided  as liquid -filled  soft gelatin  capsules  for oral administration. 
Each  capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl  polyoxylglycerides. The 
inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated 
hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and 
black  iron oxide.  Enzalutamide  is an androgen  receptor  inhibitor.  The chemical  name  is 4-{3-4-cyano - 
3-(trifluoromethyl) phenyl -5, 5 -dimethyl-4-oxo-2-sulfanylideneimidazolidin-1- yl-2-fluoro- N- 
methylbenzamide. Enzalutamide is a white crystalline non -hygroscopic solid. It is practically 
insoluble in  water.  
 
8.2.2 Androgen deprivation therapy  
ADT  includes  agents such  as degarelix,  goserelin,  leuprolide, triptorelin,  and histerelin.  These  agents 
are long- acting  analogues of the GnRH peptide and alter the feedback  loop of FSH and LH production 
to subsequently reduce circulating testosterone levels. These agents are FDA approved and may be 
used for the purposes of ADT  in this study. These  agents are generally  administered  as a subcutaneous 
or intramuscular injection and should be administered according to manufacturer instruction. Please refer to the FDA package insert for  information. 
 
8.3 Preparation, Reconstitution, and Dispensation  
The University  of Colorado Cancer  Center  clinical  trials  team  and the PI  will assign  each patient  who 
signs a consent form a patient number. Patients will be dispensed bottles of study drug containing an 
appropriate number of capsules in order to achieve the assigned doses. Patients may be dispensed a maximum of 3 complete cycle’s capsules.  
Patients will be asked to bring  back all remaining study drug at each visit. All unused study drug and 
the amount of study drug returned will be recorded on the drug accountability form. Patients will be instructed to store the enzalutamide capsules only in the bottles dispensed.  
 
8.4 Storage, Handling,  Accountability  
8.4.1 Enzalutamide  
Enzalutamide capsules are available in bottles of 120 capsules.  These should be stored at 20°Celsius  
(C) to 25°C in a dry place with the container tightly closed. 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
27 of 46   
  
8.4.2 Handling and Accountability  
All clinical drug supplies must be kept in an appropriate, limited- access, secure place until used or 
destroyed. The investigator must maintain 100% accountability for all study medication received and 
dispensed.  Proper drug accountability includes, but is not l imited to:  
 Frequently verifying that actual inventory matches documented inventory 
 Verifying that the log is completed for the drug lot used to prepare each dose  
 Verifying that all containers used are documented accurately on the log  
 Verifying that required fields are completed accurately and  legibly  
 
If any dispensing errors or discrepancies are discovered, the PI must be notified immediately.  
 
The investigator must maintain a current inventory of all study medication delivered to the site, inventor y at the site, and records of patient use. This log must accurately reflect the drug 
accountability of the study medication at all times. The following information will be recorded at a minimum: protocol number and title, name of investigator, site identifier and number, description of 
study medication,  expiration date,  date and amount dispensed, and the date and amount returned  to the 
site by the patient, including the initials of the person dispensing and receiving the study medication. 
The log should include all required information as a separate entry for each patient to whom study 
medication is dispensed. 
 
Before  site closure,  or at appropriate intervals,  a representative  from  the PI or its designee  will perform 
clinical study material accountability and reconciliation before clinical study materials are destroyed. 
The investigator  will retain  the original  documentation regarding clinical  study material  accountability 
and destruction. 
 
The investigator will monitor any expiration date and subsequently segregate and destroy expired 
clinical study drug. 
 
9. STUDY  CONDUCT  
This trial will be conducted in  compliance with  the protocol,  good clinical  practice  (GCP),  applicable 
regulatory requirements, and International Conference on Harmonisation (ICH) guidelines.  
 
9.1 Oversight of multiple participating  sites 
Study will be conducted at multiple sites with the University of Colorado Anschutz Campus as the 
coordinating site. Dr. Kessler, as the Lead PI, will work with the Site PI(s) to insure proper training 
and conduct. 
 
A PI oversight plan has been drafted to outline the procedures for maintaining oversight, 
data monitoring and study auditing. All study sites involved will follow the process outlined in the document in order to ensure safe and accurate conduct.  
 
9.2 Arrangements for Recruitment of  Patients  
Recruitment and enrollment strategies for this study may include recruitment from the investigator’s 
local practice or referrals from other physicians. If advertisements become part of the recruitment strategy,  they will be reviewed by the institutional review board (IRB)/independent ethics committee 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
28 of 46   
  
(IEC). It is not envisioned that prisoners (or other populations that might be subject to coercion or 
exploitation) will be enrolled into this study.  
 
The study will aim to enroll at least 1 patient per month to the trial.  
 
9.3 Treatment Group  Assignments  
Patients will be assigned through the randomization process with a 1:1 ratio of patients in each treatment group. Randomization will occur centrally through a non- clinical project manager at the 
coordinating site. Participating sites will contact this central manager for randomization assignment during regular business hours (M- F 8-5pm).  
 
10. STATISTICAL AND QUANTITATIVE  ANALYSES  
 
10.1 Statistical  Methods  
We estimate  a 7% (2 patients)  and 32% (9 patients)  incidence of metabolic syndrome  for enzalutamide 
and ADT treated patients based on historic data 7. Historical cross- sectional data would suggest that 
almost 50% of patients on ADT will develop metabolic syndrome, however, the trial population 
proposed will be pre- selected. Twenty -eight (28) patients in each of the two groups will provide 80% 
power to detect the 25% difference using a one -sided chi -square test with a significance  level of 0.05 
(actual  alpha=0.054). 
 
10.1.1  Endpoint Analysis 
Primary  endpoint  
Metabolic syndrome incidence will be summarized by the proportion of patients with at least 3 of the 
5 pre- specified criteria within the first 12 months of therapy.  
 
Secondary endpoint 
The secondary endpoints will be presented as follows: 
Metabolic syndrome incidence will be summarized  by the proportion of patients  acquiring with at least 
3 of the 5 pre-specified criteria within the first 6 months of therapy. 
 
The change in bone turnover markers from baseline will be assessed for each treatment group. 
Measurements will be taken at day 1 of each cycle and reported as a continuous variable. A paired t - 
test will test within an arm as to whether the change from baseline to each time point is significantly 
different from zero. 
 
The change in bone density, free fat mass, and fat mass will be measured at baseline, 3 months and 12 months and assessed for each treatment group. A paired t- test will test within an arm as to 
whether the chang e from baseline to each time point is significantly different from zero.  
 
The change in QOL scores as measured by the FACT -P and SHIM at each visit, will be assessed in 
each treatment group.  
 
Median time to PSA progression as defined in section 7.2. Time t o PSA progression is defined as the 
time from randomization to the earliest objective evidence of PSA progression as defined per  
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
29 of 46   
  
protocol.  If a patient has had a decline in PSA while on study, the PSA progression date is defined 
as the time from documented PSA nadir to an increase in PSA with confirmation as defined by 
protocol. Time to radiographic progression is defined as the time from randomization to the earliest 
objective evidence of radiographic progression as defined per protocol. Patients will be monitored at regular intervals for PSA change and radiographic change. Log rank test will be used to compare the 
distributions of above variables between the group treated with enzalutamide to the group on 
standard  ADT.  
 
The change in marker s of inflammation as measured by circulating hs- CRPwill be obtained at the 
beginning of each cycle. 
 
Adverse events data will be summarized using tables and descriptive statistics.  
 
The change in SPPB from baseline to 12 months will be measured as a continuous outcome. A 
clinically relevant change is a change in total score of 1, with a standard deviation at baseline of 1.5  
42. 
 
Mean, standard deviation, median, and range will be reported for each outcome at each time p oint, 
and the mean and standard deviation of the changes, will be calculated. One- group t -test will be used 
to estimate  effect  size of each outcome measure and test if the change  is significant at 0.05 significance 
level. Pearson or Spearman correlation co efficients will be used to assess the association between 
continuous variables.  
 
10.1.2  Accrual  
The study center treats approximately 6 -7 patients monthly who would be eligible for enrollment in 
the trial.  We estimate that 3 -4 patients will enroll a month. 
 
10.2 Safety  population 
The safety population is defined as all patients who receive at least 1 dose of either enzalutamide or ADT.  This population will be used for all safety analyses as well as efficacy analyses.  
 
10.3 Metabolic syndrome population 
The metabolic s yndrome population is defined as patients who have received at least 1 dose of either 
drug, have baseline values and at least 1 post- baseline assessment.  
 
10.4 Secondary endpoint  population 
Defined as patients who have received at least 1 dose of either drug, have baseline values and at least 1 post- baseline assessment.  
 
 
11. SAFETY  ANALYSIS  
The safety  population will be used for the analysis  of the toxicities  and AEs.  Individual toxicities  will 
be summarized by their frequency and intensity for each treatment group. Safety will be evaluated  by 
the incidence of AEs,  severity  and type of AEs,  and by changes from  baseline in the patient’s vital 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
30 of 46   
  
signs, weight, and clinical laboratory results using the safety population. Exposure to study drug and 
reasons for discontinuation will be tabulated.  
Treatment related AEs that occur after administration of the first dose of study drug and through 30 days after the last dose of study drug will be tabulated.  AEs will be tabulated  according to the Medical 
Dictionary for Regulatory Activities  (MedDRA)  and will include  the following  categories:  
• Drug -related  AEs 
• Grade 3 or higher AEs 
• Grade 3 or higher drug- related  AEs 
• The most  commonly reported treatment -emergent  AEs (i.e., those events  reported by 
≥ 10% of all patients) 
• SAEs  
 
A listing of AEs resulting in study discontinuation will be provided. 
 
Descriptive statistics for the actual values of clinical laboratory parameters (and/or change from baseline in clinical  laboratory parameters)  will be presented  for all scheduled  measurements over time.  
 
All concomitant medications collected from screening through the study period will be classified to 
preferred terms according to the World Health Organization (WHO) drug dictionary. 
 
Additional safety analyses may be performed to most clearly enumerate rates of toxicities and to further define the safety profile of enzalutamide and ADT. 
 
11.1 Oversight and Monitoring 
The Lead  Principal  Investigator  (PI) will be responsible for monitoring the trial per the trial monitoring 
plan, in addition to overseeing the safety and efficacy of the trial, executing the DSM plan, and 
complying with all reporting requirements to local and federal authorities. This oversight will be 
accomplished  through  additional oversight  from  the Data  and Safety  Monitoring  Committee  (DSMC) 
at the University of Colorado Cancer Center (CU Cancer Center). The DSMC is responsible for ensuring data quality and patient safety for all clinical studies at the CU Cancer Center. A summary of the DSMC’s activities is as follows:  
 
• Conduct of internal  audits  
• Ongoing review of all serious adverse events (SAEs), unanticipated problems (UAPs) and 
reportable adverse events (AEs)  
• Has the authority to close and/or suspend trials for safety or trial conduct  issues  
• May submit recommendations for corrective actions to the CU Cancer Center’s Executive 
Committee  
 
Per the CU Cancer Center Institutional DSM Plan, SAEs, UAPs and reportable AEs are reported to 
the DSMC, IRB and the sponsor per study protocol. All SAEs, UAPs and reportable AEs are to be 
reported to the DSMC within 5 business days of receiving notification of the occurrence. 
 
Each  subject’s treatment  outcomes will be discussed  by the Site PI(s)  and appropriate  staff at regularly 
scheduled disease- oriented working group meetings. Data regarding number of subjects, significant 
toxicities, dose modifications, and treatment responses will be discussed and documented in the meeting’s minutes. 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
31 of 46   
  
 
The Lead PI in this multi -site trial is responsible for organi zing and conducting monthly 
teleconferences with all participating sites. The Lead PI will also be responsible for including data 
from  all of the participating  sites to include the minutes from  these  regularly  scheduled  teleconferences 
between the Lead PI and the sites within the overall trial’s six -month DSM report.  
 
The Lead PI will provide a DSM report to the CU Cancer Center DSMC on a six -month basis. The 
DSM report will include a protocol summary; current enrollment numbers; summary of toxicity data to include specific SAEs,  UAPs  and AEs;  any dose modifications; all protocol  deviations;  and protocol 
amendments.  The DSM  report to the DSMC  will also include, if applicable,  the results  of any efficacy 
data analysis conducted, as well as any internal DSMB reports. Results and recommendations from 
the review  of this six-month report  by the DSMC  will then need  to be submitted by the site to the IRB 
of record at the time of continuing review.  
 
12. ADVERSE  EVENTS  
12.1 Definitions  
 
Definition of Adverse Events (AEs)  
An adverse event (AE) is defined as any untoward medical occurrence in a subject administered a 
study drug and which does not necessarily have a causal relationship with this treatment. An AE can 
therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a study drug, whether or not related to the 
study drug. 
 
An abnormality identified during a medical test (e.g., laboratory parameter, vital sign, ECG data, physical  exam) should be defined  as an AE only if the abnormality meets one of the following criteria:  
• Induces clinical signs or  symptoms.  
• Requires active intervention.  
• Requires interruption or discontinuation of study medication. 
• The abnormality or investigational value is clinically significant in the opinion of  the 
investigator.  
 
All adverse events,  whether  or not related  to the study drug, must  be fully  and completely  documented. 
 
Definition of Serious Adverse Events (SAEs)  
An AE is considered “serious” if, in the view of either the investigator or sponsor, is unexpected and 
is potentially related to study participation and it results in any of the following outcomes: 
• Results in  death, 
• Is life threatening (an AE is considered “life -threatening” if, in the view of either the 
investigator or sponsor, its occurrence places the subject at immediate risk of death. It  does 
not include an AE that, had it occurred in a more severe form, might have caused  death.), 
• Results in persistent or significant disability/incapacity or substantial disruption of the 
ability to conduct normal life functions, 
• Results in congenital anomaly, or birth defect,  
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
32 of 46   
  
• Requires inpatient hospitalization or leads to prolongation of hospitalization (hospitalization 
for treatment/observ ation/examination caused by AE is to be considered as serious),  
• Other medically important events.  
 
Serious Adverse Event Reporting  
For patients on enzalutamide therapy, w ithin 48 hours of awareness of a serious adverse event,  
whether or not related  to enzalutamide, the Investigator will complete and submit a Medwatch 
3500A Form, containing all required information (reference 21 CFR 312.32). The Investigator  will 
submit a copy of this MedWatch  3500A form  to FDA and Astellas  by either  e-mail or fax, within  the 
same timeframe if subject is on enzalutamide.  If submission of this SAE  to FDA or Astellas or is not 
possible within 48 hours, the Investigator’s local drug safety contact (IRB, etc.) should be informed by phone. 
 
The SAE documentation, including the Medwatch 3500A Form and available source records should 
be emailed or faxed to:  
 
Astellas Pharma Global Development – United States 
Email: Safety -us@us.astellas.com  
Fax number: (847) 317-1241 
 
The following minimum information is required:  
• Study number/IIT regulatory identifier  
• Subject number, sex and age 
• The date of  report  
• A description of the SAE (event, seriousness of the event)  
• Causal relationship to the study drug 
 
Follow-up information for the event should be sent within promptly (within 7 days) as necessary. 
 
All SAEs , regardless of treatment arm, will be reported to the University of Colorado DSMC within 
48 hours of awareness of the event.  
 
 
Procedure in Case of Pregnancy  
The effect  of enzalutamide  in pregnant and lactating  women  is not known, and the exposure of a fetus 
or nursing infant  is considered a potential risk. Enzalutamide can  cause  fetal harm  when  administered 
to a pregnant woman based on its mechanism of action. Subjects receiving enzalutamide are advised 
to use 2 acceptable methods of birth  control (one of which  must  include a condom as a barrier  method 
of contraception) starting  at the time of screening  for an enzalutamide study and continuing throughout 
the course of treatment and for at least three months after enzalutamide is  discontinued. 
 
If during the conduct of the clinical trial, a male subject impregnates his partner, the subject should 
report the pregnancy to the Investigator. The Investigator should report th e pregnancy to the Sponsor 
as an SAE within 24 hours of awareness of the event. The expected date of delivery or expected date of the end of the pregnancy, last menstruation, estimated fertility date, pregnancy result and neonatal 
data etc., should be incl uded in this information. 
 
The Investigator should report the outcome of the pregnancy (independent of outcome, eg. full term delivery, pre -term delivery, spontaneous abortion, induced abortion, stillbirth, death of newborn, 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
33 of 46   
 congenital anomaly [including anomaly in a miscarried fetus, etc] in accordance with the same 
reporting procedure as for SAEs. The date of outcome of the pregnancy, gestational age, date of  birth 
and neonatal data etc., should be included in this information. 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
34 of 46   
  
 
12.2 Maintenance  of Safety  Information 
Safety information will be maintained in a clinical database/repository in a retrievable format. At a 
minimum, at the end of the treatment phase (=”last patient off treatment”) as well as the end of the 
follow-up phase (=”last patient out”) of the Study, the Principal Investigator shall provide all adverse 
events, both serious and non- serious, in report format. However, in certain circumstances more 
frequent review of the safety data may be necessary, e/g/ to fulfill a regulatory requ est, and as such 
the data shall be made available within a reasonable timeframe at Astellas, Inc.’s request.  
 
 
12.2.1  Product Quality  Complaints  
Any product quality complaint, with or without an AE, (including reports of suspicion of 
counterfeiting, diversion, or tampering, and suspected transmission of pathogens) will be transmitted 
by the Principal Investigator within 24 hours of becoming aware of the event(s).  
 
 
 
 
12.3 Monitoring of Adverse Events and Period of  Observation  
AEs, both non-serious and serious (which include all deaths), will be monitored throughout the study 
as follows:  
• AEs will be reported  from  the time  of consent through  30 days after  administration  of the  last 
dose of study drug and recorded.  
• Serious pretreatment events will be reported to Astellas, Inc. from the time of the signing of 
the informed consent form (ICF) up to first dose of study drug. 
• SAEs will be reported to Astellas, In c. from the time of consent through 30 days after 
administration of the last dose of study drug and recorded. All SAEs should be monitored 
until they are resolved  or are clearly  determined to be due to a patient’s  stable  or chronic 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
35 of 46   
  
condition or intercurrent illness (es). If an SAE occurs in the follow -up period and is thought 
to be possibly related to study drug, it must be reported. 
 
13. ADMINISTRATIVE  REQUIREMENTS  
This is an investigator -initiated trial and thus major trial decisions and document design will occur 
with the PI and supporting institution, the University of Colorado Cancer Center. Astellas Inc. is 
providing study support and thus will have access to trial data and patient safety information. 
 
13.1 Data Quality Assurance  
The investigator  is required to prepare and maintain adequate and accurate case histories designed to 
record all observations and other data pertinent to the study for each study patient. Study monitors 
will discuss instances of missing or uninterpretable data with the in vestigator for resolution. Any 
changes to study data will be monitored via an audit trail. 
 
13.2 Study  Monitoring  
Monitoring for this study will be performed by CU Cancer  Center  Clinical  Monitor  in accordance with 
the clinical monitoring plan (CMP), incorporate d herein by reference. The CMP describes in detail 
who will conduct the monitoring, at what frequency monitoring will be done, at what level of detail monitoring will be performed, and the distribution of the monitoring reports.  
 
The CMP will be approved by the PI and will be followed to comply with GCP guidelines. All study 
records must be consistent with the patient’s source documentation. During the course of the study, 
the study monitor will make  study site visits  to review  protocol  compliance,  verify  study record  against 
source documentation, assess drug accountability, and ensure that the study is being conducted 
according to pertinent regulatory requirements. The review of medical records will be performed in a 
manner that ensures that patient confidentiality is  maintained. 
 
Independent audits  will be conducted by the CU Cancer  Center  DSMC  to ensure monitoring practices 
are performed  consistently  across all participating  sites,  if applicable, and that monitors are following 
the CMP.  
 
13.3 Ethical  Considerations  
The study will be conducted in accordance with applicable regulatory requirement(s) and will adhere 
to GCP standards. The IRB/IEC will review all appropriate study documentation to safeguard the 
rights, safety, and well -being of the patients . The protocol, Investigator Brochure (IB), ICF, 
advertisements (if applicable),  written  information  given  to the patients  (including  diary cards),  safety 
updates, annual progress  reports, and any revisions to these documents will be provided  to the IRB/IEC 
by the investigator, as allowed by local regulations.  
 
13.4 Patient Information and Informed  Consent  
After the study has been fully explained, written informed consent will be obtained from either the 
patient  or his/her  guardian or legal  representative before  study participation.  The method of obtaining 
and documenting the informed consent and the contents of the consent must comply with the ICH - 
GCP and all applicable regulatory  requirements.  
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
36 of 46   
  
13.5 Patient  Confidentiality  
To maintain patient privacy, study drug accountability records, study reports, and communications 
will identify the patient by initials where permitted and/or by the assigned patient number. The patient’s confidentiality will be maintained and will not be made publicly availabl e to the extent 
permitted by the applicable laws and regulations. 
 
13.6 Investigator Compliance  
Changes to the protocol will require written IRB/IEC approval/favorable opinion before 
implementation,  except when  the modification is needed  to eliminate  an immediate  hazard  or hazards 
to patients.  When  immediate  deviation  from  the protocol is required  to eliminate  an immediate  hazard 
or hazards to patients, the investigator will contact Astellas, Inc., or a designee, if circumstances permit,  to discuss the planned course  of action.  Any departures from  the protocol  must  be documented. 
 
13.7 On-site Audits  
Regulatory authorities,  the IRB,  and/or Astellas,  Inc. may  request  access to all source documents, and 
any study documentation for on- site audit or inspection. Direct access to these documents must be 
guaranteed by the investigator, who must provide support at all times for these activities.  
 
13.8 Investigator and Site Responsibility for Drug  Accountability  
Accountability for the study drug at the trial site is the responsibility of the investigator. Please see 
section 8.4.2 for details.  
 
All material containing study drug will be treated and disposed of in accordance with gover ning 
regulations.  
 
13.9 Closure of the  Study  
Study participation may be prematurely terminated if, in the opinion of the investigator or Astellas, Inc., there is sufficient reasonable cause. Written notification documenting the reason for study termination will be provided by the terminating party. 
 
Circumstances that may warrant termination include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to patients  
• Failure to enter patients at an acceptable  rate 
• Insufficient adherence to protocol  requirements  
• Insufficient, incomplete, and/or unevaluable  data 
 
13.10  Record  Retention  
The investigator will maintain all study records according to the ICH -GCP and applicable regulatory 
requirement(s).  Records will be retained  for at least 3 years  after the last patient  is removed  from  trial 
or according to applicable regulatory requirement(s). If the investigator withdraws from the 
responsibility of keeping the study records, custody must be transferred to a person willing to accept 
the responsibility.  
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
37 of 46   
  
14. USE OF  INFORMATION 
Upon completion of the clinical study and evaluation of results by the hospital or institution and/or 
investigator may publish or disclose the clinical trial results pursuant to the terms contained in the applicable Clinical Trial Agreement.  
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
38 of 46   
  
15. REFERENCES  
1. Siegel  R, Ma J, Zou Z, Jemal  A. Cancer  statistics,  2014. CA Cancer  J Clin 2014;64:9- 
29. 
2. Pound CR, Partin AW, Eisenberger  MA, Chan DW, Pearson JD, Walsh PC. Natural 
history of progression after PSA elevation following radical prostatectomy. Jama 
1999;281:1591-7. 
3. Bianco  F, Dotan  ZA, Kattan  MW,  et al. Duration of response to androgen deprivation 
therapy  and survival after subsequent biochemical  relapse in men initially  treated  with radical 
prostatectomy. J Clin Oncol 2004;22:4552, abstr  
4. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia  associated 
with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997;79:933-41. 
5. van Andel G, Kurth  KH. The impact  of androgen  deprivation therapy  on health  related 
quality of life in asymptomatic men with lymph node positive prostate cancer. Eur Urol 2003;44:209-14. 
6. Potosky AL, Knopf K, Clegg LX, et al. Quality -of-life outcomes after primary 
androgen  deprivation therapy:  results  from  the Prostate  Cancer  Outcomes  Study.  J Clin Oncol 
2001;19:3750-7. 
7. Braga -Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with 
prostate cancer undergoing long- term androgen -deprivation therapy. J Clin Oncol 
2006;24:3979-83. 
8. Smith DS, Carvalhal GF, Schneider K, Krygiel J, Yan Y, Catalona WJ. Quality -of- 
life outco mes for men with prostate carcinoma detected by screening. Cancer 2000;88:1454- 
63. 
9. Saad F, Olsson C, Schulman CC. Skeletal morbidity in men with prostate cancer: 
quality-of- life considerations throughout the continuum of care. Eur Urol 2004;46:731-39; 
discussion 9-40. 
10. Fossa  SD, Woehre H, Kurth  KH, et al. Influence of urological morbidity on quality of 
life in patients with prostate cancer. Eur Urol 1997;31 Suppl 3:3-8. 
11. Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health- related 
quality o f life after contemporary therapies for localized prostate cancer. J Clin Oncol 
2002;20:557-66. 
12. Kiratli BJ, Srinivas S, Perkash  I, Terris  MK. Progressive decrease in bone density over 
10 years of androgen deprivation therapy in patients with prostate cancer. Urology 
2001;57:127-32. 
13. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive 
osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000;163:181- 6. 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
39 of 46   
  
14. Clay CA, Perera S, Wagner JM, Miller ME, Nelson JB, Greenspan SL. Physical 
function in men with prostate cancer on androgen deprivation therapy. Phys Ther 
2007;87:1325-33. 
15. Joly F, Alibhai SM, Galica  J, et al. Impact  of androgen  deprivation therapy  on physical 
and cognitive function, as well as quality of life of patients  with nonmetastatic  prostate cancer. 
J Urol  2006;176:2443-7. 
16. Sadetsky  N, Greene K, Cooperberg MR, Hubbard A, Carroll  PR, Satariano  W. Impact 
of androgen  deprivation on physical  well-being  in patients  with prostate cancer:  analysis  from 
the CaPSURE  (Cancer  of the Prostate  Strategic  Urologic  Research  Endeavor) registry.  Cancer 
2011;117:4406-13. 
17. Bylow K, Hemmerich J, Mohile SG, Stadler  WM, Sajid S, Dale W. Obese frailty, 
physical performance deficits, and falls in older men with biochemical recurrence of  prostate 
cancer on androgen deprivation therapy: a case-control study. Urology 2011;77:934-40. 
18. Lakka HM, Laaksonen DE, Lakka TA, et al . The metabolic syndrome and total and 
cardiovascular disease mortality in middle -aged men. Jama 2002;288:2709-16. 
19. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US 
adults: findings from the third National Health and Nutrition Examination Survey. Jama 2002;287:356-9. 
20. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. 
Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004;22:2546-53. 
21. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and 
cardiovascular disease mortality in middle -aged men. JAMA : the journal of the American 
Medical Association  2002;288:2709-16. 
22. Phillips GB, Jing TY, Resnick LM, Barbagallo M, Laragh JH, Sealey JE. Sex 
hormones and hemostatic risk factors for coronary heart disease in men with hypertension. Journal of hypertension 1993;11:699-702. 
23. Smith  JC, Bennett  S, Evans LM, et al. The effects  of induced hypogonadism on arterial 
stiffness, body composition, and metabolic parameters in males with prostate cancer. The Journal of clinical endocrinology and metabolism 2001;86:4261-7. 
24. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone 
suppression in men with prosta te cancer leads to an increase in arterial stiffness and 
hyperinsulinaemia. Clinical science  2003;104:195-201. 
25. Laaksonen DE, Niskanen  L, Punnonen K, et al. Testosterone and sex hormone-binding 
globulin predict the metabolic syndrome and diabetes in middle -aged men. Diabetes care 
2004;27:1036-41. 
26. Alibhai SM, Duong -Hua M, Sutradhar R, et al. Impact of androgen deprivation 
therapy on cardiovascular disease and diabetes. Journal of clinical oncology : official  journal 
of the American Society of Clinical Oncology 2009;27:3452-8. 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
40 of 46   
  
27. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular 
disease during androgen deprivation therapy: observational study of veterans with prostate 
cancer. Journal of the National Cancer Institute 2010;102:39-46. 
28. Tombal B, Borre M, Rathenborg P, et al. Enzalutamide monotherapy in hormone - 
naive prostate cancer: primary analysis of an open -label, single -arm, phase 2 study. Lancet 
Oncol 2014;15:592-600. 
29. Cella D, Hackshaw M , Diaz J , et al. Quality of life ( QoL) among patients with 
renal  cell carcinoma  (RCC)  treated with pazopanib versus  sunitinib  in the COMPARZ 
study. J Clin Oncol 2013; 31:suppl 6; abstr  346. 
30. Scher HI, Fizazi K, Saad F, et al. Increased Survival with Enzalutamide in Prostate 
Cancer after Chem otherapy. N Engl J Med 2012. 
31. Medivation and Astellas Announce the Phase 3 PREVAIL Trial of Enzalutamide 
Meets Both Co -Primary Endpoints of Overall Survival and Radiographic Progression- Free 
Survival in Chemotherapy -Naive Patients  With  Advanced  Prostate  Cancer.  Medivation, 2013. 
(Accessed January 4, 2014, at 
32. Smith M, Borre M, Rathenborg P, al e. Efficacy and safety of enzalutamide 
monotherapy in hormone -naive prostate cancer. In: 2013 ASCO Annual Meeting; 2013; 
Chicago, IL; 2013. p. abstract 5001. 
33. www.astellas.us/docs/us/12A005- ENZ -WPI.pdf  AHopiX.  
34. Scher  HI, Beer  TM, Higano CS, et al. Antitumour activity  of MDV3100 in castration - 
resistant prostate cancer: a phase 1 -2 study. Lancet 2010;375:1437-46. 
35. Common Terminology Criteria for Adverse Events (CTCAE). In; 2010. 
36. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the 
metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev  2005;13:322-7. 
37. Visser  M, Fuerst  T, Lang  T, Salamone L, Harris  TB. Validity  of fan-beam  dual- energy 
X-ray absorptiometry for measuring fat -free mass and leg muscle mass. Health, Aging, and 
Body Composition Study --Dual -Energy X -ray Absorptiometry and Body Composition 
Working Group. J Appl Physiol 1999;87:1513-20. 
38. Chen Z, Wang Z, Lohman T, et al. Dual -energy X -ray absorptiometry is a valid tool 
for assessing skeletal muscle mass in older women. J Nutr 2007;137:2775-80. 
39. Haseen F, Murray LJ, Cardwell CR, O'Sullivan JM, Cantwell MM. The effect of 
androgen deprivation t herapy on body composition in men with prostate cancer: systematic 
review and meta- analysis. J Cancer Surviv  2010;4:128-39. 
40. Segal  RJ, Reid  RD, Courneya KS, et al. Resistance  exercise in men receiving  androgen 
deprivation therapy for prostate cancer. J Clin  Oncol 2003;21:1653-9. 
41. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy 
scale: development and validation of the general measure. Journal of clinical oncology : official journal of the American Society of Clinical Oncology  1993;11:570-9. 
COMIRB/Protocol # 14 -0909  
Protocol Version: 
4.27.2018  PI:  Dr. Kessler  
41 of 46   
  
42. Pahor M, Blair SN, Espeland M, et al. Effects of a physical activity intervention on measures  of 
physical  performance:  Results  of the lifestyle  interventions and independence for Elders Pilot (LIFE -P) 
study. The journals of gerontology Series A, Biological sciences and medical sciences  2006;61:1157-65. 
43. Oken  MM,  Creech  RH, Tormey  DC, et al. Toxicity  and response criteria  of the Eastern Cooperative 
Oncology Group. Am J Clin Oncol 1982;5:649- 55. 
 